Member Info for Hedgehog100

Torreaguas,

On 17th. July, RMS announced that it had entered into an exclusivity arrangement and agreed outline non-binding heads of terms in respect of a potential acquisition of a company that operates in the fast growing medtech and biosecurity sectors, subject to the completion of mutual due diligence by both parties .

Most companies would then take months to sign a binding agreement.

But barely a month later, on 21st. August, RMS announced that it had signed a binding Share Purchase Agreement for the acquisition of 100% of the share capital of Pharm2Farm, subject to regulatory and RMS shareholder approval.

As regards waivers, where did you get the three weeks figure from?

Eve Sleep for example took over two months (6th. December 2018 to 11th. February 2019), albeit that included the holiday period.

Delays are a part of business and investment life, but there are very few operators as quick and decisive as Trevor Brown.
And the sanitizer episode if anything was a sign of that, not the reverse.

Acuere,

It could even be faster than six months.
The Blue Earth Diagnostics FDA approval only took 6 months under a priority review, and that was without the increased imperative that COVID-19 has created for POLX's technology.

Also, I believe that the FDA will then give an answer on the priority review request within 45 days.
This is different from a fast track request, which is where the 60 days figure comes from.

"PMA Review Process
... Within 45 days after a PMA is received by FDA, the agency will notify the applicant whether the application has been filed. The letter will include the PMA reference number and the date FDA filed the PMA. Expedited review status, if appropriate, may be communicated at this time. ..."
https://www.fda.gov/medical-devices/premarket-approval-pma/pma-review-process

"Priority review
From Wikipedia, the free encyclopedia
Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. ..."
https://en.wikipedia.org/wiki/Priority_review

"Fast track (FDA)
From Wikipedia, the free encyclopedia
Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need. Fast Track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and attempt to make a decision within sixty days. ..."
https://en.wikipedia.org/wiki/Fast_track_(FDA)

"'Tech unicorn' Octopus Energy to create 1,000 new UK jobs

Firm says it wants to help Britain become ‘best place to invest in clean energy’

Octopus Energy plans to create 1,000 new technology jobs across sites in London, Brighton, Warwick and Leicester, and a new tech hub in Manchester, as part of its vision to make the UK the “Silicon Valley of energy”.

... The prime minister, Boris Johnson, said the new jobs will “provide exciting opportunities across the country for those who want to be at the cutting edge of the global green revolution”.

... Octopus became the UK’s latest “tech unicorn” (a startup company valued at more than $1bn) in May this year after the Australian energy company Origin paid £300m for a 20% stake. It has since announced a £100m push into the US market, as part of its goal to reach 100 million energy customers around the world by 2027. ..."

https://www.theguardian.com/business/2020/oct/05/tech-unicorn-octopus-energy-to-create-1000-new-uk-jobs

25th Jun 2020 10:01 am RNS £1.1m Raised in Oversubscribed Placing
"Katoro Gold PLC (AIM: KAT), the gold and nickel exploration and development company, is pleased to announce that is has raised £1.1m (gross), through an oversubscribed placing and subscription of new ordinary shares at 1.5 pence per share (the 'Fundraise').
... "I am delighted with the support shown from our current shareholders and welcome a number of new high net worth investors to our register. This is indicative of the significant progress Katoro Gold has made over the last 6 months on our strategic base and precious metal portfolio. The Company is particularly pleased that funding in the latest oversubscribed placing was offered directly to the Company, originating from current and new high net worth investors who are eager to see the developing business model gain further traction." ..."
https://www.lse.co.uk/rns/KAT/16311m-raised-in-oversubscribed-placing-h4bbfqm2zyxr7cn.html

2nd Oct 2019 2:49 pm RNS Fundraise
"Katoro Gold PLC (AIM: KAT), the Tanzanian focused exploration and development company, is pleased to announce that is has raised £100,000 (gross), through a placing and subscription of new ordinary shares at 1.0p per share (the 'Fundraise'). ..."
https://www.lse.co.uk/rns/KAT/fundraise-ad781oe01il4e16.html

Tom,

Those are KAT's last two placings copied above.

As you can see, the £100K. placing a year ago was only followed by the last nearly nine months later.

So as that last one was for £1.1m., and was barely three months ago, no further placing is due soon.

In conclusion, the company is well-funded for the period of transformational newsflow coming shortly, which could have a quite explosive impact on the s.p.

Note also that the last placing had warrants at 3p per share.

Two big important pieces of RMS news are imminent:

1. RMS Pharm2Farm acquisition takeover offer waiver.
2. Nanotechnology anti-viral facemask proof of concept.

Though not necessarily in that order.

So we should get a double boost to the s.p.: to big boosts in quick succession.

KAT's Blyvoor gold tailings project is "finance ready".

This means that it is ready for finance, not that the finance is already in place.

Some investors have apparently misunderstood the term, and unfairly accused LC of lying.

Being finance ready in mining terms is quite late stage for a mining explo. company, and means that the project is close to starting production.

"CORPORATE PRESENTATION JULY 2020
... BLYVOOR GOLD TAILINGS PROJECT, SOUTH AFRICA
... The Project is finance ready, with the debt equity to be raised at project level, minimising Katoro Gold share dilution. ..."
https://katorogold.com/wp-content/uploads/2020/07/Katoro-Gold-Presentation-July-2020_Final.pdf

"Get Finance Ready
Pilot Fish are advising clients to make it as easy as possible for your bank to say 'yes' by getting finance ready. By this we mean preparing your documentation and reports. ..."
https://www.pilotfishpartnership.co.uk/get-finance-ready-.html

30th Sep 2020 7:00 am RNS Timing of update on Q3 trading & strategic review

Audioboom (AIM: BOOM), the leading global podcast company, announces that the Company will provide a trading update for the quarter ended 30 September 2020 on or around 14 October 2020. At that time, the Company will also provide an update on the strategic review, incorporating the formal sale process (as referred to in the City Code on Takeovers and Mergers, the "Code") announced on 19 February 2020.



The Company remains in an "offer period" as defined in the Code and the dealing disclosure requirements as stated in the Company's announcement of 10 February 2020 continue to apply. A further update will be made as appropriate.

https://www.lse.co.uk/rns/BOOM/timing-of-update-on-q3-trading-strategic-review-jxrfbessbpyptag.html

" ... AISC sub 800! All permits in place.
... A resource proven tailings project is pretty much a no brainier once it has the environmentals and the finance.
Trek"

The Concept Of AISC In The Gold Mining Industry: Strength And Weakness
Jan. 6, 2015 7:53 AM ET
https://seekingalpha.com/article/2799985-the-concept-of-aisc-in-the-gold-mining-industry-strength-and-weakness

"I've lost money here and have no interest in buying again ever."

LOL,

You've just proved my point about your lying!

You're gagging to buy in again, and you know it!!

If not, you would just move on.

Yes Tom,

it was a pump & dump by Sean, which is one of the reasons why he has no credibility.

And now it's 'troll & buy'.

Sean is a joke: he doesn't even know the difference between a mine and a mining project, or that small mining explorers look to sell their projects to majors rather than developing the mine themselves.

In conclusion, a lying, market abuse troll!

Sean83 Posted in: KAT Posts: 292 Price: 2.90 Strong Buy
RE: Filter the derampers 29 Sep 2020 08:23
"seen ariana resources update on 30m jv?
They have a market cap 9x higher than KAT yet only have 1.5m oz gold.
This is so undervalued it's unreal. Still a very strong buy at these levels"

Sean,

Does the 'filter the derampers' advice now apply to you?!

You are a 'buy high, sell low' merchant, and your nonsense has no credibility.

Thanks Copout & Paulus.

1st Oct 2020 7:00 am RNS Financial Adviser and Joint Broker Appointment
"Digitalbox plc (AIM: DBOX), the mobile-first digital media business, which owns Entertainment Daily and The Daily Mash, announces that it has appointed Panmure Gordon (UK) Limited ("Panmure Gordon") as Financial Adviser and Joint Broker, with immediate effect, alongside WH Ireland who are Nominated Adviser and Joint Broker and Alvarium who are Joint Broker, to the Company."
https://www.lse.co.uk/rns/DBOX/financial-adviser-and-joint-broker-appointment-16twe95ip82lmi8.html

1st Oct 2020 7:01 am RNS Acquisition, Subscription and Board Update
"Digitalbox plc (AIM: DBOX), the mobile-first digital media business, which owns Entertainment Daily and The Daily Mash, today announces the acquisition of the entire issued share capital of Tab Media Limited ("Tab Media") for a cash consideration of £750,000 (the "Acquisition").
In conjunction with the Acquisition, the Company announces a proposed direct subscription to raise £1.2 million, before expenses, through a subscription for 24,489,795 new ordinary shares in the Company at a subscription price of 4.9 pence per ordinary share by Downing Strategic Micro-Cap Investment Trust plc (the "Subscription"). The Subscription is conditional on shareholders' approval at a general meeting of the Company. The Acquisition is not conditional on the Subscription or on shareholders' approval. ...
The Subscription Price represents a discount of 2.0% to the closing price of 5.0 pence on 30 September 2020. The Subscription Shares represent 26.7% of the Company's existing issued share capital at the date of this announcement and will represent 21.1% of the Company's enlarged issued share capital immediately following the issue of the Subscription Shares.
The Subscription is conditional, inter alia, upon the approval by Shareholders at a general meeting of the Company which is expected to be convened on or around 19 October 2020 (the "General Meeting"). ...
Pursuant to the Subscription Agreement, Robin Miller, Chairman of the Company, has indicated his willingness to resign as Chairman and step down from the Board. Robin will remain in his role and oversee a smooth transition of his responsibilities until a successor is appointed.
The Company will immediately commence a search process for independent non-executive chairman candidates, and a further update in this regard will be made in due course. ..."
https://www.lse.co.uk/rns/DBOX/acquisition-subscription-and-board-update-e4px9zn73so0hvl.html

Yes Genericname, you tend to find that a share price will appreciate a lot during the FDA approval process, in anticipation of the approval.

And with its relatively recent fundraising POLX is fully-funded for the FDA approval process ... in which there's not the same real risk of rejection as with drugs, where there can be unpleasant side effects.

In a sector where it can take a decade or more to bring a drug to market, a year will be regarded as pretty close by most investors.

And it could potentially be a lot sooner than a year: an expediated review is quite possible.

From the POLX Vox Markets video of 19th June 2020 (not quoted verbatim) :
"• POLX will also be looking at the possibility of an expedited FDA review.
• Research users will inform and drive this expedited review request.
• The vaccines and anti-viral sides of COVID-19 are being speeded up, so the diagnostics side should also be speeded up."

As research users are key to an expediated FDA review, it's encouraging that POLX have said this today:
"The installation of new polarisers has continued and users of our systems are publishing research at an increased rate, expanding and deepening the knowledge base of the use of hyperpolarised 129Xe in pulmonary medicine, while further validating Polarean's technology."

"Technical Analysis for KAT - Katoro Gold Plc"

"Grade Last Price % Change Price Change
grade A 2.72 -6.21% -0.18"

"ADX Long Term Intermediate Term Short Term
Strong Up Up Up"

https://lse.swingtradebot.com/equities/KAT:LSE

Added to the company's existing cash, this new facility can provide very useful extra liquidity at a very cheap price:

8th Sep 2020 7:00 am RNS Unaudited Interim Results
" ... Furthermore, the cash balance has increased from £0.5 million at 31 December 2019 to £1.2 million at 30 June 2020. ..."
https://www.lse.co.uk/rns/DBOX/unaudited-interim-results-2r1pm0zlnbd186g.html

Could it be a prelude to an acquisition?

25th Sep 2020 7:00 am RNS New borrowing facility agreed

"Funding Update

Digitalbox plc (AIM: DBOX), the mobile-first digital media business, which owns Entertainment Daily and The Daily Mash, announces that, in order to strengthen the balance sheet and aid liquidity, the Company has secured a £450,000 five year term loan facility under the British Business Bank's Coronavirus Business Interruption Loans Scheme (CBILS) from its bankers, National Westminster Bank plc (the "Facility").

The Facility can be drawn down at any point before 9 December 2020 with a 12 month interest-free period following drawdown and an interest rate of 2.48% per annum on the drawn down amount thereafter. The funds are repayable commencing 12 months after drawdown in equal monthly instalments for the remaining four years. There will be no penalty for making early repayment(s) of all or part of the Facility."

https://www.lse.co.uk/rns/DBOX/new-borrowing-facility-agreed-wjwm3gbm2caygt2.html

29-Sep-20 08:19:23 0.634 46,380 Buy* 0.60 0.65 294.05 O
29-Sep-20 13:44:50 0.5866 46,380 Sell* 0.58 0.62 272.07 O

RMS's interim results unveiled on Friday, and their accompanying statement, were excellent.

And the personnel, technology, and financial management here are first class.
The company is doing a great deal with relatively little compared to some others, which seem to be hemorrhaging money.

Pharm2Farm's projects give the upside of an exciting drug developer, but without such lengthy timescale, costs, and risks.

And at a fraction of the market cap. of many of them.

Callit,

That lower estimate of £2.5M. facemasks profit per month equates to £30M. profit p.a.

Not including potential worldwide licensing.

And masks will be just one of Pharm2Farm's products.

And PharmtoFarm is just one of RMS's three subsidiaries, along with GyroMetric and Cloudveil.

Wiltshireman,

Have you only just noticed that RMS is no longer a drone company, and hasn't been for a while.

The only AERO days are long gone.

How is it desperation to get rid of poor businesses and acquire much better ones?

It's just good business sense.